We are live on ! Find out more
CAM

Cormorant Asset Management Portfolio holdings

AUM $1.99B
1-Year Est. Return 737.95%
This Fund
S&P 500
This Quarter Est. Return
+41.62%
1 Year Est. Return
+737.95%
3 Year Est. Return
+5,256.52%
5 Year Est. Return
+13,483.26%
10 Year Est. Return
+564,575.55%
AUM
$1.43B
AUM Growth
+$108M
Cap. Flow
-$133M
Cap. Flow %
-9.27%
Top 10 Hldgs %
45.41%
Holding
87
New
7
Increased
18
Reduced
17
Closed
14

Top Buys

Rank Stock Value
1
GOSS icon
Gossamer Bio
GOSS
+$37.2M
2
APLS
Apellis Pharmaceuticals
APLS
+$31.2M
3
ACLX
Arcellx
ACLX
+$29.2M
4
ARQT icon
Arcutis Biotherapeutics
ARQT
+$22.7M
5
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$20.3M

Top Sells

Rank Stock Value
1
TPTX
Turning Point Therapeutics, Inc. Common Stock
TPTX
+$187M
2
CCXI
ChemoCentryx, Inc.
CCXI
+$35.3M
3
FMTX
Forma Therapeutics Holdings, Inc. Common Stock
FMTX
+$21.9M
4
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$21.3M
5
ITCI
Intra-Cellular Therapies Inc.
ITCI
+$15.7M

Sector Composition

Rank Sector Weight
1 Healthcare 99.37%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RXDX
1
DELISTED
Prometheus Biosciences, Inc. Common Stock
RXDX
$117M 8.16%
1,979,158
-50,000
-2% -$2.29M
APLS
2
DELISTED
Apellis Pharmaceuticals
APLS
$101M 7.06%
1,478,000
+528,000
+56% +$31.2M
DSGN icon
3
Design Therapeutics
DSGN
$751M
$83.6M 5.84%
5,000,000
-500,000
-9% -$9.95M
ERAS icon
4
Erasca
ERAS
$6.15B
$81.9M 5.73%
10,505,554
– –
ACLX
5
DELISTED
Arcellx
ACLX
$57.2M 4%
3,049,173
+1,524,173
+100% +$29.2M
MLTX icon
6
MoonLake Immunotherapeutics
MLTX
$1.56B
$47.1M 3.29%
6,065,001
– –
ALT icon
7
Altimmune
ALT
$568M
$44M 3.07%
3,442,863
+442,863
+15% +$6.54M
MRTX
8
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$40.2M 2.81%
575,000
+275,000
+92% +$20.3M
RVMD icon
9
Revolution Medicines
RVMD
$38.5B
$39.3M 2.75%
1,995,066
– –
JBIO
10
Jade Biosciences
JBIO
$1.18B
$38.6M 2.7%
66,591
+17,143
+35% +$11.4M
GOSS icon
11
Gossamer Bio
GOSS
$101M
$38.3M 2.68%
3,198,382
+3,000,000
+1,512% +$37.2M
TARS icon
12
Tarsus Pharmaceuticals
TARS
$2.55B
$33.8M 2.36%
1,971,422
+96,422
+5% +$1.53M
KRTX
13
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
$33.7M 2.36%
150,000
+25,000
+20% +$5.06M
RNAM
14
DELISTED
Avidity Biosciences
RNAM
$32.9M 2.3%
2,012,115
– –
IMRX icon
15
Immuneering
IMRX
$262M
$32.7M 2.29%
2,286,181
– –
BMEA icon
16
Biomea Fusion
BMEA
$88.2M
$31M 2.17%
3,170,872
– –
EWTX icon
17
Edgewise Therapeutics
EWTX
$4.28B
$30M 2.1%
3,051,989
-798,011
-21% -$8.06M
BHVN
18
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$27.9M 1.95%
184,894
– –
VTYX
19
DELISTED
Ventyx Biosciences
VTYX
$27.3M 1.9%
780,646
+3
+0% +$66
VRDN icon
20
Viridian Therapeutics
VRDN
$2.2B
$26.9M 1.88%
1,310,000
+432,500
+49% +$7.78M
GLUE icon
21
Monte Rosa Therapeutics
GLUE
$1.82B
$24.5M 1.71%
2,993,717
– –
GRNA
22
DELISTED
GreenLight Biosciences Holdings, PBC Common Stock
GRNA
$23.8M 1.66%
10,261,560
+3,301,020
+47% +$8.64M
AXNX
23
DELISTED
Axonics, Inc. Common Stock
AXNX
$22.7M 1.59%
322,240
– –
SRPT icon
24
Sarepta Therapeutics
SRPT
$1.64B
$22.1M 1.55%
+200,000
New +$20.2M
COGT icon
25
Cogent Biosciences
COGT
$6.76B
$21.6M 1.51%
1,450,000
+700,000
+93% +$9.59M
1
2 3 4

Similar funds

SC
Syon Capital San Francisco, California $1.99B AUM 22.67% 1-Year Est. Return
RMCM
Reynders McVeigh Capital Management Boston, Massachusetts $1.98B AUM 23.37% 1-Year Est. Return
RCM
Rivernorth Capital Management West Palm Beach, Florida $2B AUM 0.66% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
MYAM
Meiji Yasuda Asset Management Tokyo, Japan $2B AUM 22.52% 1-Year Est. Return
CCA
Checchi Capital Advisers Beverly Hills, California $1.98B AUM 19.17% 1-Year Est. Return
LBC
Lowe Brockenbrough & Co Richmond, Virginia $2.01B AUM 22.05% 1-Year Est. Return
C
Consulta London, United Kingdom $2.01B AUM 16.82% 1-Year Est. Return

Cormorant Asset Management's Q3 2022 Portfolio in Review

As of Q3 2022, Cormorant Asset Management held 87 positions worth $1.43B, up 8.2% from $1.32B the previous quarter. Its ten largest holdings account for 45% of the portfolio.

Cormorant Asset Management withdrew a net $133M in Q3 2022, closing 14 positions and reducing 17 holdings. Its most notable exit was Turning Point Therapeutics, Inc. Common Stock, an estimated $187M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 95% a quarter earlier.

Against the trend, Cormorant Asset Management opened a new position in Arcutis Biotherapeutics worth $19.1M.

  • Cormorant Asset Management's largest Q3 2022 buy was Arcutis Biotherapeutics: 1,000,000 shares worth $19.1M.
  • Cormorant Asset Management added most to Gossamer Bio in Q3 2022, an estimated $37.2M increase.
  • Cormorant Asset Management's biggest Q3 2022 reduction was Design Therapeutics, cutting an estimated $9.95M.
  • Cormorant Asset Management fully exited Turning Point Therapeutics, Inc. Common Stock in Q3 2022, selling an estimated $187M.
  • Cormorant Asset Management's ten largest holdings make up 45% of its $1.43B portfolio in Q3 2022.
  • Cormorant Asset Management opened 7 new positions and closed 14 in Q3 2022.
  • Cormorant Asset Management's portfolio value rose 8.2% quarter-over-quarter to $1.43B.

Based on Cormorant Asset Management's 13F filing for Q3 2022, filed 14 Nov 2022.